NZ326352A - Hydroxamic acid based collagenase inhibitors useful in the treatment of and prophylaxis of disorders in which the overproduction of soluble CD23 is implicated - Google Patents
Hydroxamic acid based collagenase inhibitors useful in the treatment of and prophylaxis of disorders in which the overproduction of soluble CD23 is implicatedInfo
- Publication number
- NZ326352A NZ326352A NZ326352A NZ32635297A NZ326352A NZ 326352 A NZ326352 A NZ 326352A NZ 326352 A NZ326352 A NZ 326352A NZ 32635297 A NZ32635297 A NZ 32635297A NZ 326352 A NZ326352 A NZ 326352A
- Authority
- NZ
- New Zealand
- Prior art keywords
- soluble
- implicated
- prophylaxis
- treatment
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compounds of described formula wherein R and R3 are each independently hydrogen, alkyl, alkenyl, alkynyl or aryl; R1 is arylmethyl; and R2 is alkyl, alkenyl, aryl, cycloalkyl or cycloalkenyl, and pharmaceutically acceptable derivatives thereof, are useful in the treatment and prophylaxis of disorders associated with excess production of soluble CD23 (s-CD23) such as autoimmune disease and allergy is implicated. Human CD23 exists as two differentially regulated isoforms, a and b, which differ only in the amino acids at the intracellular N-terminus. In humans, the constitutive a is only found on B-lymphocytes, whereas type b , inducible by IL-4, is found on all cells capable of expressing CD23. Because of the various properties of CD23, compounds that inhibit the formation of soluble CD23 should have twofold actions a)enhancing negative feedback inhibition of IgE synthesis by maintaining levels of intact, cell bound CD23 (i-CD23), on the surface of the B cells, and b)inhibiting the immunostimulatory cytokine activities of higher molecular weight soluble fragments. In addition, inhibition of CD23 cleavage should mitigate sCD23-induced monocyte activation and mediator activation and mediator formation, thereby reducing inflammatory response.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9601041.8A GB9601041D0 (en) | 1996-01-17 | 1996-01-17 | Novel compounds |
| PCT/EP1997/000196 WO1997026257A1 (en) | 1996-01-17 | 1997-01-14 | Hydroxamic acid based collagenase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ326352A true NZ326352A (en) | 2000-03-27 |
Family
ID=10787226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ326352A NZ326352A (en) | 1996-01-17 | 1997-01-14 | Hydroxamic acid based collagenase inhibitors useful in the treatment of and prophylaxis of disorders in which the overproduction of soluble CD23 is implicated |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0912545A1 (en) |
| JP (1) | JP2000503312A (en) |
| KR (1) | KR19990077325A (en) |
| CN (1) | CN1213368A (en) |
| AR (1) | AR005472A1 (en) |
| AU (1) | AU725056B2 (en) |
| BR (1) | BR9707024A (en) |
| CA (1) | CA2242913A1 (en) |
| CZ (1) | CZ222498A3 (en) |
| GB (1) | GB9601041D0 (en) |
| HU (1) | HUP9901022A3 (en) |
| IL (1) | IL125381A0 (en) |
| NO (1) | NO983283L (en) |
| NZ (1) | NZ326352A (en) |
| PL (1) | PL327820A1 (en) |
| TR (1) | TR199801380T2 (en) |
| TW (1) | TW462967B (en) |
| WO (1) | WO1997026257A1 (en) |
| ZA (1) | ZA97345B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| GB9609795D0 (en) * | 1996-05-10 | 1996-07-17 | Smithkline Beecham Plc | Novel compounds |
| WO2000040713A1 (en) * | 1999-01-06 | 2000-07-13 | Mcmaster University | Method of preventing immune and hypersensitivity reactions |
| GB9922825D0 (en) * | 1999-09-25 | 1999-11-24 | Smithkline Beecham Biolog | Medical use |
| AU2001271068A1 (en) * | 2000-07-18 | 2002-01-30 | Chugai Seiyaku Kabushiki Kaisha | Matrix metalloprotease inhibitors |
| WO2003064472A2 (en) * | 2002-01-28 | 2003-08-07 | Aimsco Limited | Treatment of ms with goat serum |
| US7521563B2 (en) | 2004-08-10 | 2009-04-21 | Shizuoka Coffein Co., Ltd. | Hydroxamic acid derivative and medicine containing the same as active ingredient |
| KR100844277B1 (en) * | 2005-04-29 | 2008-07-07 | (주)아모레퍼시픽 | A hydroxamic acid derivative and the preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743587A (en) * | 1985-09-10 | 1988-05-10 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| GB9504084D0 (en) * | 1995-03-01 | 1995-04-19 | British Biotech Pharm | Synthesis of carboxylic and hydroxamic acid derivatives |
-
1996
- 1996-01-17 GB GBGB9601041.8A patent/GB9601041D0/en active Pending
-
1997
- 1997-01-14 IL IL12538197A patent/IL125381A0/en unknown
- 1997-01-14 EP EP97901055A patent/EP0912545A1/en not_active Withdrawn
- 1997-01-14 NZ NZ326352A patent/NZ326352A/en unknown
- 1997-01-14 HU HU9901022A patent/HUP9901022A3/en unknown
- 1997-01-14 WO PCT/EP1997/000196 patent/WO1997026257A1/en not_active Application Discontinuation
- 1997-01-14 PL PL97327820A patent/PL327820A1/en unknown
- 1997-01-14 CA CA002242913A patent/CA2242913A1/en not_active Abandoned
- 1997-01-14 BR BR9707024A patent/BR9707024A/en unknown
- 1997-01-14 CZ CZ982224A patent/CZ222498A3/en unknown
- 1997-01-14 CN CN97192982A patent/CN1213368A/en active Pending
- 1997-01-14 TR TR1998/01380T patent/TR199801380T2/en unknown
- 1997-01-14 KR KR1019980705472A patent/KR19990077325A/en not_active Application Discontinuation
- 1997-01-14 JP JP9525693A patent/JP2000503312A/en active Pending
- 1997-01-14 AU AU14436/97A patent/AU725056B2/en not_active Ceased
- 1997-01-15 AR ARP970100153A patent/AR005472A1/en unknown
- 1997-01-16 ZA ZA97345A patent/ZA97345B/en unknown
- 1997-01-30 TW TW086101017A patent/TW462967B/en active
-
1998
- 1998-07-16 NO NO983283A patent/NO983283L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL125381A0 (en) | 1999-03-12 |
| HUP9901022A2 (en) | 1999-07-28 |
| WO1997026257A1 (en) | 1997-07-24 |
| AR005472A1 (en) | 1999-06-23 |
| CA2242913A1 (en) | 1997-07-24 |
| CZ222498A3 (en) | 1999-03-17 |
| GB9601041D0 (en) | 1996-03-20 |
| NO983283L (en) | 1998-09-16 |
| BR9707024A (en) | 1999-07-20 |
| JP2000503312A (en) | 2000-03-21 |
| KR19990077325A (en) | 1999-10-25 |
| NO983283D0 (en) | 1998-07-16 |
| ZA97345B (en) | 1998-07-16 |
| AU725056B2 (en) | 2000-10-05 |
| TW462967B (en) | 2001-11-11 |
| CN1213368A (en) | 1999-04-07 |
| HUP9901022A3 (en) | 2001-11-28 |
| TR199801380T2 (en) | 1998-10-21 |
| EP0912545A1 (en) | 1999-05-06 |
| PL327820A1 (en) | 1999-01-04 |
| AU1443697A (en) | 1997-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY117527A (en) | Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present | |
| AU6226494A (en) | Spiroazacyclic derivatives as substance p antagonists | |
| YU65803A (en) | Xanthine derivative, production and use thereof as a medicament | |
| AR014886A1 (en) | 4,5-DIARILIMIDAZOLES 2-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE FOR THE MANUFACTURE OF MEDICINES | |
| MX9606334A (en) | Azeotrope-like compositions of 1,1,1,3,3-pentafluoropropane. | |
| MX9708663A (en) | Il-6 activity inhibitor. | |
| DE69333731D1 (en) | GLIALMITOGENIC FACTORS, THEIR MANUFACTURE AND USE | |
| AU3110999A (en) | Disubstituted pyrazolines and triazolines as factor xa inhibitors | |
| NO980313D0 (en) | N- (Aroyl) glycine hydroxamic acid derivatives and related compounds | |
| HUP9702035A2 (en) | Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them | |
| DE69316236D1 (en) | SUBSTITUTED AMIDINE COMPOUNDS, THEIR PRODUCTION AND TREATMENT METHODS | |
| MY109522A (en) | Substituted pyrazoles | |
| DE69833654D1 (en) | BIARYL ALKANIC ACIDS IN USE AS CELL ADHESION INHIBITORS | |
| MY133159A (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
| NZ326352A (en) | Hydroxamic acid based collagenase inhibitors useful in the treatment of and prophylaxis of disorders in which the overproduction of soluble CD23 is implicated | |
| HUP0102477A2 (en) | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases and pharmaceutical compositions containing the compounds | |
| ATE369844T1 (en) | JAK/STAT PATHWAY INHIBITORS AND THEIR USE IN THE TREATMENT OF GENERAL PRIMARY OSTEOARTHRITIS | |
| AU4064597A (en) | Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof | |
| AU2003210203A1 (en) | Aqueous dispersions consisting of polycarbodiimides | |
| MD1753B2 (en) | Herbicidal composition and process for weed control in the cereals growing zones | |
| Masuda et al. | Inhibitory effect of cytostatin on spontaneous lung metastases of B16-BL6 melanoma cells | |
| AP2000002001A0 (en) | Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the tnf relaease. | |
| WO2003033024A1 (en) | Cell proliferation inhibitor | |
| EP0145361A3 (en) | Acetylene derivatives for the treatment of hypertension and angina | |
| RS20050421A (en) | Aminoindazole derivatives and use thereof as kinase inhibitors |